GlassScriptPhysician profile
Alla Adler
NPI 1972076107
$11,513.92
in general payments reported to CMS, 2019-2025
46 companies · $2,552 in 2025
The $2,552 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,031 · 2022: $2,624 · 2023: $2,776 · 2024: $2,531 · 2025: $2,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,836 · Education: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,836.12 |
| Education | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,645.39 | 2021-2023 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $1,264.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,138.96 | 2021-2025 | Farxiga, Lokelma |
| Abbott Laboratories | $722.49 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $684.84 | 2021-2025 | |
| Dexcom, INC. | $657.42 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $655.40 | 2021-2025 | Korlym |
| Amgen INC. | $629.70 | 2021-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $615.92 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $462.86 | 2022-2025 | Omnipod |
| Abbvie INC. | $432.12 | 2021-2025 | Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.24 | 2021-2025 | Jardiance |
| Intra-Sana Laboratories | $182.79 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Tandem Diabetes Care, INC. | $161.97 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $154.05 | 2024-2025 | Rezdiffra |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.